{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274261","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.461434+00:00","generated_at":"2026-05-16T22:32:03.129133+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta advances NKX019 into second dose cohort; cash runway into 2029","bullets":["Enrollment in second dose-escalation cohort of NKX019 for autoimmune diseases is underway.","Lymphodepletion with fludarabine+cyclophosphamide shows deep B-cell depletion in all patients vs. partial with cyclophosphamide alone.","Cash, cash equivalents, and investments of $316.5M as of Sept 30, 2025, expected to fund operations into 2029.","Net loss of $21.7M ($0.29 per share) for Q3 2025; R&D expenses $20.2M.","Preliminary data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274261","json":"https://secwatch.observer/filing/0001193125-25-274261.json","markdown":"https://secwatch.observer/filing/0001193125-25-274261.md","text":"https://secwatch.observer/filing/0001193125-25-274261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000119312525274261/0001193125-25-274261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000119312525274261/nktx-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:32:03.129133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}